[1]
T. Mudzviti, M. Sibanda, S. Gavi, C. C. Maponga, and G. D. Morse, “Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program”, J Infect Dev Ctries, vol. 6, no. 11, pp. 806–808, Nov. 2012.